Activity of three β-lactams (ertapenem, meropenem and ampicillin) against intraphagocytic Listeria monocytogenes and Staphylococcus aureus
Open Access
- 28 April 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 55 (6) , 897-904
- https://doi.org/10.1093/jac/dki094
Abstract
Objectives: Assessment of the activity of three β-lactams [ertapenem (a carbapenem with a prolonged half-life), meropenem and ampicillin] against intraphagocytic Listeria monocytogenes and Staphylococcus aureus. Methods: Quantitative measurements of cfu changes in broth and in THP-1 macrophages (post-phagocytosis) over time (5 and 24 h) at concentrations spanning from sub-MICs to Cmax (maximal concentration typically observed in patients' serum upon administration of conventional doses); morphological studies using an electron microscope; evaluation of drug stability (HPLC), protein binding (equilibrium dialysis) and measurement of drug cellular accumulation (microbiological assay). Results: Ertapenem was unable to control L. monocytogenes growth in THP-1 macrophages at all concentrations and times tested, even under conditions where ampicillin and meropenem were bactericidal. This behaviour could not be ascribed to drug instability, protein binding or lack of cell accumulation in comparison with ampicillin or meropenem. Ertapenem, ampicillin and meropenem were equally effective at reducing the post-phagocytosis inoculum of S. aureus (∼1 log cfu), and caused conspicuous changes in the morphology of intracellular bacteria consistent with their lysis. These effects were obtained, however, only at large multiples (100-fold or more) of the MIC maintained over 24 h. Because of the high intrinsic antimicrobial potency of the β-lactams studied, these concentrations were below the Cmax. Conclusions: Ertapenem will probably be ineffective against intraphagocytic forms of L. monocytogenes for reasons that remain to be discovered. Conversely, ertapenem could be an alternative to ampicillin and meropenem against intraphagocytic S. aureus since its longer half-life may allow high concentrations to be maintained for more prolonged times.Keywords
This publication has 30 references indexed in Scilit:
- An update on the medical management of listeriosisExpert Opinion on Pharmacotherapy, 2004
- Antibiotic-induced persistence of cytotoxic Staphylococcus aureus in non-phagocytic cellsJournal of Antimicrobial Chemotherapy, 2004
- Activity of beta-lactams (ampicillin, meropenem), gentamicin, azithromycin and moxifloxacin against intracellular Listeria monocytogenes in a 24 h THP-1 human macrophage modelJournal of Antimicrobial Chemotherapy, 2003
- Influence of P-Glycoprotein Inhibitors on Accumulationof Macrolides in J774 MurineMacrophagesAntimicrobial Agents and Chemotherapy, 2003
- Pharmacodynamic Assessment of Ertapenem (MK-0826) against Streptococcus pneumoniae in a Murine Neutropenic Thigh Infection ModelAntimicrobial Agents and Chemotherapy, 2002
- Discrepancy between Uptake and Intracellular Activity of Moxifloxacin in a Staphylococcus aureus -Human THP-1 Monocytic Cell ModelAntimicrobial Agents and Chemotherapy, 2002
- A New Model Examining Intracellular and Extracellular Activity of Amoxicillin, Azithromycin, and Clarithromycin in Infected CellsChemotherapy, 1993
- Activity of antibiotics against microorganisms ingested by mononuclear phagocytesEuropean Journal of Clinical Microbiology & Infectious Diseases, 1991
- Intracellular distribution and activity of antibioticsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1991
- Establishment and characterization of a human acute monocytic leukemia cell line (THP‐1)International Journal of Cancer, 1980